Compares two anti-rejection drugs after pancreas and kidney transplant in type 1 diabetes
Tests sirolimus versus mycophenolate in adults with type 1 diabetes and kidney failure.
Key facts
- Who runs it
- Institute For Clinical And Experimental Medicine
- Where
- Prague, CzechiaSee the site
- Registry title
- SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 9 Sept 2020
- Expected to end
- 31 May 2028
- Type of study
- Interventional
- Record updated
- 8 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes and advanced kidney failure who are due to be listed for a combined pancreas and kidney transplant from a deceased donor.
- Age
- 18 to 65 years (the registry also lists a maximum age of 64 years)
- Sex
- Men and women can join.
- Disease stage
- Pre-end-stage or end-stage kidney failure caused by type 1 diabetes.
- Earlier treatment
- Cannot have had a previous kidney transplant alone. Cannot have had a major abdominal operation or a hernia in the abdominal wall.
- Biomarker or test result
- Cannot have a positive T-cell cross-match on the latest blood sample. Cannot have a high immune risk (PRA above 50%).
Main reasons for not taking part
- Pregnant or breastfeeding
- Allergy or intolerance to any drug in either treatment plan
- Active or significant liver disease
- Cancer now or in the past (except treated localized skin cancer without return)
- Kidney from a living donor, a partial pancreas transplant, or donor older than 65 years
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- 1 Male or female patients, of 18 to 65 years of age, with a pre- or an end-stage renal failure, Type 1-diabetic nephropathy
- Patient is scheduled to be put on waiting-list for a primary simultaneous pancreas/kidney (SPK) cadaver transplant
Who cannot take part
- Patient receives a kidney transplant from a living donor, or receives segmental pancreatic transplant, or a previous kidney transplant alone
- Patient has a history of an extensive abdominal operation or a hernia in the abdominal wall
- Patient is allergic or intolerant to any drug comprising both immunosuppressive protocols
- Patient has malignancy or history of malignancy, with the exception of adequately treated localized squamous cell or basal cell carcinoma, without recurrence
- Patient has any form of substance abuse, psychiatric disorder or condition, which, in the opinion of the investigator, may invalidate communication
- Patient has a positive T-cell cross-match on the most recent serum specimen
- Patient is known for active liver disease or has significant liver disease; defined by ASAT and ALAT serum levels greater than 3 times the upper limit of normal
- Donor is older than 65 years of age
- Patient is pregnant or breastfeeding
- Patient has a high immunological risk, defined as a PRA grade > 50%
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Czechia
- Institute for Clinical and Experimental MedicinePrague, CzechiaTaking people
About the trial
What the trial wants to find out
To compare the incidence of incisional hernia following combined pancreas and kidney transplantation in type 1 diabetic subjects with end-stage kidney disease treated with to different immunosuppressive rengimens
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
- Plain-language title
- Compares two anti-rejection drugs after pancreas and kidney transplant in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Criteria questions
- Built from 2024-517391-38-00, who can take part
- Record updated
- 8 October 2024